ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity
ACSL4 suppresses anti-tumor immunity in CRC by modulating the RIG-I-MAVS-IFN pathway, highlighting ACSL4 as a promising target for CRC immunotherapy.
Authors
- Qixiang Zhao (ORCID: https://orcid.org/0009-0000-0335-032X)
- Dongquan Jing (ORCID: https://orcid.org/0009-0001-2501-1633)
- Qiuhua Cao (ORCID: https://orcid.org/0009-0004-5974-2014)
- Yiming Liu (ORCID: https://orcid.org/0009-0008-1776-6076)
- Juan Du (ORCID: https://orcid.org/0000-0001-8190-3524)
- Yanting Lin (ORCID: https://orcid.org/0000-0002-6719-2815)
- Ning Liu (ORCID: https://orcid.org/0000-0002-7009-9187)
- Xiaoyun Han
- Xinghua Gao (ORCID: https://orcid.org/0000-0003-3575-9466)
- Rui Gao (ORCID: https://orcid.org/0000-0002-2074-9997)
- Yiming Ren (ORCID: https://orcid.org/0009-0001-0562-0618)
- Xingyu Jiang (ORCID: https://orcid.org/0009-0008-3043-819X)
- Huijuan Da
Institutions
- China Pharmaceutical University (CN)
- Ningxia Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Neoplasia
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1016/j.neo.2025.101194
- Citations
- 5
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 6.97
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
- Key Research and Development Program of Ningxia
- Graduate Research and Innovation Projects of Jiangsu Province
- Fundamental Research Funds for the Central Universities